Genmab A Asset Turnover Ratio (GMAB), as of fourth quarter 2025, current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Genmab A  (NASDAQ: GMAB)
 

Genmab A Asset Turnover Ratio

Quarterly Results, Trends, Rankings, Statistics

Genmab A asset turnover ratio, the ability of Genmab A's assets to generate revenue in the fourth quarter 2025, increased sequentially to 0.41 in the fourth quarter (Dec 31 2025), yet the ratio remained below the average, as GMAB's position remain challenging.

Within sector 164 more businesses have achieved higher asset turnover ratio. While ranking the asset turnover ratio, among all other companies, it is fair to say, that the company's position has deteriorated in the fourth quarter 2025 compared to the preceding quarter from to 3436.

Asset Turnover Ratio Definition


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GMAB Asset Turnover Ratio (Dec 31 2025)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Jun 30 2024)
II. Quarter
Y / Y Asset Change 35.06 % 111.74 % -11.27 % 174.53 % 71.81 %
Y / Y Revenue Change 169.18 % - 104.42 % - 71.65 %
Asset Turnover Ratio (TTM) 0.41 - 0.38 - 0.46
GMAB's Total Ranking # 3436 # # # #
Seq. Asset Change 0 % 99.15 % -49.79 % 35.06 % 56.78 %
Seq. Revenue Change - - - - 35.94 %



Asset Turnover Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 165
Healthcare Sector # 511
Overall Market # 3436

Asset Turnover Ratio Statistics
High Average Low
3.82 3.17 2.5
(Dec 31 2020)   (Dec 31 2022)




GMAB Company Profile • Back to GMAB Efficiency Comparisons • Compare GMAB Asset Turnover Ratio to its Competitors



Companies with similar Asset Turnover Ratio for the quarter ending Dec 31 2025, within Healthcare Sector Asset Turnover Ratio Revenues for 12 Months ending Dec 31 2025 Assets at quarter ending Dec 31 2025
Omada Health Inc   0.99 $ 259.186  Millions$ 261.685  Millions
Kiniksa Pharmaceuticals International Plc  0.99 $ 677.564  Millions$ 684.111  Millions
Axsome Therapeutics Inc   0.98 $ 638.496  Millions$ 648.878  Millions
Orthofix Medical Inc   0.98 $ 822.017  Millions$ 835.890  Millions
National Healthcare Corp  0.98 $ 1,517.781  Millions$ 1,552.401  Millions
Ensysce Biosciences Inc   0.97 $ 5.067  Millions$ 5.205  Millions
Alphatec Holdings Inc   0.97 $ 763.888  Millions$ 788.556  Millions
Embecta Corp   0.97 $ 1,079.400  Millions$ 1,114.825  Millions
Argenx Se  0.97 $ 8,399.366  Millions$ 8,682.698  Millions
Cerus Corporation  0.96 $ 205.288  Millions$ 214.223  Millions
Fortrea Holdings Inc   0.95 $ 2,723.400  Millions$ 2,853.500  Millions
Pacs Group Inc   0.95 $ 5,288.932  Millions$ 5,551.874  Millions
Strata Skin Sciences Inc  0.95 $ 29.429  Millions$ 30.941  Millions
Select Medical Holdings Corp  0.95 $ 5,452.830  Millions$ 5,743.891  Millions
Neuroone Medical Technologies Corp  0.95 $ 8.716  Millions$ 9.212  Millions
Ufp Technologies Inc   0.93 $ 602.410  Millions$ 646.300  Millions
Accuray Incorporated  0.93 $ 436.226  Millions$ 470.396  Millions
Community Health Systems Inc   0.93 $ 12,485.000  Millions$ 13,493.500  Millions
Neuropace Inc   0.92 $ 99.220  Millions$ 107.285  Millions
Lftd Partners Inc   0.92 $ 36.921  Millions$ 40.014  Millions
Corcept Therapeutics Inc  0.92 $ 761.407  Millions$ 827.109  Millions
Docgo Inc   0.91 $ 322.196  Millions$ 352.486  Millions
Indivior Pharmaceuticals Inc   0.91 $ 1,240.000  Millions$ 1,361.000  Millions
Novavax inc   0.90 $ 1,123.479  Millions$ 1,246.486  Millions
Adma Biologics Inc   0.90 $ 508.113  Millions$ 565.470  Millions
Pediatrix Medical Group Inc   0.90 $ 1,913.849  Millions$ 2,135.420  Millions
Genedx Holdings Corp   0.89 $ 427.173  Millions$ 481.976  Millions
Lakeland Industries Inc   0.88 $ 192.648  Millions$ 218.770  Millions
Ardelyx inc   0.87 $ 407.320  Millions$ 466.184  Millions
Travere Therapeutics Inc   0.87 $ 490.728  Millions$ 561.970  Millions



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.